Stock Abbreviation: Sanxin Medtec
Stock Code: 300453
Jiangxi Sanxin Medtec Co., Ltd.
(No. 999 Fushan Avenue, Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province)
Summary of the Prospectus for the Issuance of Convertible Corporate Bonds to Non-Specific Targets
Sponsor (Lead Underwriter): Sinolink Securities Co., Ltd.
(No. 95 Dongcheng Gen Shangjie, Qingyang District, Chengdu)
July 2026
Statement
Any decision or opinion made by the China Securities Regulatory Commission (CSRC) or the stock exchange regarding this issuance does not imply their guarantee of the authenticity, accuracy, or completeness of the application documents and disclosed information, nor does it constitute a substantive judgment or guarantee of the issuer's profitability, investment value, or investor returns. Any statement to the contrary is a false representation.
In accordance with the Securities Law, after the securities are issued in accordance with the law, the issuer is solely responsible for changes in its operations and earnings. Investors shall independently judge the investment value of the issuer, make their own investment decisions, and bear the investment risks arising from changes in the issuer's operations and earnings or fluctuations in securities prices after the issuance.
Important Notice
The company specifically reminds investors to carefully read the full text of the prospectus before making investment decisions and to pay special attention to the following important matters:
- Credit Rating of the Company's Convertible Corporate Bonds
This issuance of convertible corporate bonds has been rated by China Chengxin International Credit Rating Co., Ltd. According to the "Credit Rating Report for the 2025 Issuance of Convertible Corporate Bonds to Non-Specific Targets by Jiangxi Sanxin Medtec Co., Ltd." (Zhongpengxinping [2025] No. Z [1734] 01) issued by the rating agency, the issuer's entity credit rating is AA-, the rating outlook is stable, and the bond credit rating is AA-. The rating date is October 21, 2025.
In accordance with regulatory requirements and the tracking rating system of China Chengxin International Credit Rating Co., Ltd., the agency will conduct periodic and non-periodic tracking ratings on the issuer during the duration of the bonds. The agency will continuously monitor factors such as changes in the issuer's external operating environment, business or financial status, and debt repayment guarantees to track credit risks.
- Risks Related to the Issuer
The company requests that investors carefully read the full text of "Section III: Risk Factors" in the prospectus and pay special attention to the following risks:
(1) Risk of Adverse Impact of Volume-Based Procurement Policies on Operating Performance
Currently, some domestic hemodialysis medical consumables have been subject to inter-provincial alliance volume-based procurement. For example, the Henan Provincial Healthcare Security Administration announced the "Inter-provincial Alliance Volume-based Procurement Document for Hemodialysis Medical Consumables" in January 2024, covering 23 provinces and autonomous regions. In May 2024, the administration issued a notice requiring the implementation of winning bid prices starting in June 2024 for a one-year procurement cycle. Additionally, the Tianjin Pharmaceutical Procurement Center initiated the Beijing-Tianjin-Hebei "3+N" alliance procurement for similar products.
In the future, if the company's products fail to win bids or if the sales volume increase after winning bids is insufficient to offset price declines, the company's operating performance may be adversely affected.
(2) Risks of Overseas Operations and Foreign Trade
The international political and economic situation is complex and volatile. Political and economic instability in parts of the Middle East and Africa, along with global "trade wars" and frequent changes in tariff policies, have made the company's overseas operating environment more complex. Overseas revenue accounted for 15.09%, 18.27%, and 22.49% of total revenue during the reporting period. Adverse changes in the overseas operating environment or trade policies could negatively impact the company's international business.